# Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

> **NCT03815890** · PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 80 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03815890
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-04
- **Primary completion:** 2031-01-01
- **Final completion:** 2033-01-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03815890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03815890, "Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03815890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*